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resulting from the adenosine-induced vasodilation in the peripheral circulation is another undesirable effect. Overall, these side effects limit the usefulness of adenosine in pharmacologic stress testing. Because a number of side effects induced by adenosine appear to be mediated by AdoR types other than the A 2A receptor, it is likely that selective agonists of A 2A receptors may be more vascular specific and cause fewer undesirable effects than adenosine.
The ultra-short duration of coronary vasodilation by adenosine also makes it a less-thanan-ideal-agent for pharmacologic stress testing, as it is inconvenient to infuse adenosine intravenously for 4-6 min during pharmacologic stress testing. Several potent, high-affinity, and selective A 2A AdoR agonists have been developed (Alberti, 1997; Belardinelli et al., 1998; Glover et al., 1996; Shryock et al., 1998) . However, the clinical use of these compounds may be limited because of their high affinity for the receptor, which yields an excessively prolonged duration of action and may cause significant hypotension. A novel, selective, moderate-affinity, A 2A AdoR agonist-the 2-(N-pyrazolyl) adenosine derivative, CVT-3146-has been developed (Gao et al., 2001a) . Our previous results have indicated that CVT-3146 causes a longer and more potent coronary vasodilation in conscious dogs than adenosine, but is not associated with the magnitude of hypotension seen with adenosine (Trochu et al., 2003) .
The aims of this study were to compare the vasodilator effects of CVT-3146 and adenosine on coronary and peripheral circulations and their effects on cardiac output in conscious dogs. JPET #53306 catheter was inserted into the distal abdominal aorta for the measurement of blood pressure, and an electromagnetic flow transducer (25 mm, Carolina Medical Electronic Inc., King, NC) was placed around the abdominal aorta just above the iliac bifurcation for the measurement of LBF.
Doppler ultrasonic flow transducers were placed around the superior mesenteric artery and left renal artery for measurements of the mesenteric blood flow (MBF) and renal blood flow (RBF), respectively. The abdomen was closed in layers. The catheter and wires were run subcutaneously and exited from the back of the dog's neck. The dogs were allowed to recover from the surgery for 10-14 days and were trained to lie on the laboratory table quietly.
Recording From Chronically Instrumented Dogs
Arterial pressure was measured by connecting the previously implanted catheter to a strain-gauge transducer (Statham P23 ID, Newark, NJ), and mean arterial pressure (MAP) was derived using a 2Hz low-pass filter. Heart rate was monitored from the pressure pulse interval using a cardiotachometer (Beckeman Instruments, Newark, NJ).
Effects of CVT-3146 or Adenosine on the Coronary Blood Flow and the Cardiac Output:
The coronary flow velocity was measured from the ultrasonic flow transducer using a pulsed Doppler flow meter (System 6, Triton Technology, San Diego, CA). The mean coronary flow velocity was derived using a 2Hz low-pass filter. CBF (ml/min) was calculated using the formula provided by the vendor. CO (ml/min) was measured from the electromagnetic flow transducer using an electromagnetic flow meter (Carolina Medical Electronic Inc., King, NC).
Late diastolic coronary resistance (LDCR) and total peripheral resistance (TPR) were calculated as diastolic arterial pressure divided by late diastolic coronary blood flow and as MAP divided by CO, respectively. Mean and phasic signals were recorded at the same time. And a faster speed (25mm/sec) was run to allow to calculate LDCR if needed. LDCR was chosen as the index of This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on September 3, 2003 as DOI: 10.1124 at ASPET Journals on October 2, 2017 jpet.aspetjournals.org Downloaded from coronary vascular resistance since it is independent of the compressive effect of ventricular contraction on coronary microvessels and was calculated as the quotient of late diastolic arterial blood pressure and CBF (Liang and Stone, 1982; Hintze and Vatner, 1984) . or Adenosine on the Blood Flow in the Lower Body, the Mesentery, and the Kidney: LBF was measured from the electromagnetic flow transducer using an electromagnetic flow meter (Carolina Medical Electronic Inc., King, NC). The mesenteric and renal flow velocity was measured from the flow transducers using a pulsed Doppler flow meter (System 6, Triton Technology, San Diego, CA). Mean blood flow velocities were derived using a 2Hz low-pass filter. MBF and RBF were calculated using the formula provided by the vendor.
Effects of
Mean resistances in the vascular beds were calculated as MAP divided by the mean blood flow.
Experimental Protocols
On the day of the experiment, the dog was brought to the laboratory and put on an experimental table. The previously implanted devices were attached to the recording equipment. A catheter was inserted into a peripheral vein on the leg and attached to an infusion line so that the drugs could be administered without disturbing the dog. The experiment began after the baseline hemodynamics and blood flow were stable.
Effects of CVT-3146 or Adenosine on the Coronary Blood Flow and the Cardiac Output (n=7):
A dose-response curve of CBF or CO to CVT-3146 at doses of 0.1, 0.25, 0.5, 1.0, and 2.5µg/kg was obtained following intravenous bolus injections. The dose-response curve to adenosine at doses of 10, 25, 50, 100, and 250µg/kg was obtained as well. Hemodynamics and CBF were allowed to return to the baseline before the next dose was administered. The interval between each dose was 5 to 15 min, depending on the duration of action of the agents. (10, 25, 50, 100 , and 250µg/kg) was obtained following intravenous bolus injections as well.
Materials
Adenosine was purchased from Sigma Chemical Company (St. Louis, MO), and CVT-3146 was synthesized by CV Therapeutics, Inc., (Palo Alto, CA).
Data Analysis
All data are presented as mean±SEM. The statistical significance of differences was determined using a paired t-test for the response to each injection of the drugs. The significant differences in the responses between CVT-3146 and adenosine were determined using an one-way ANOVA followed by Tukey's Test. Significant changes were considered to be P<0.05. A computerbased software package (SigamaStat 2.03) was used for statistical analysis. The second difference in CBF response to CVT-3146 and adenosine was in the duration of coronary vasodilation. As shown in Figure 2 , the duration of coronary vasodilation with adenosine (250µg/kg) was markedly shorter than that induced by CVT-3146 (2.5µg/kg). There was an increase in CBF following the injection of adenosine at a dose of 250µg/kg, but CBF returned to the baseline within 1 min. Following the injection of CVT-3146 at a dose of 2.5µg/kg, CBF remained at 2-fold above the baseline for more than 2 min. The duration of CBF 2-fold above the baseline for CVT-3146 (2.5µg/kg) and adenosine (250µg/kg) was 130±19 sec. CVT-3146 and adenosine caused significant increases in CO. CVT-3146 at doses of 0.1 and 0.25µg/kg resulted in a smaller increase in CO when compared to adenosine at doses of 10 and 25µg/kg (2.2±0.96 vs. 13±1% and 5.0±1.4 vs. 16±3%, both P<0.05). There was no significant difference in the increase in CO induced by higher doses of CVT-3146 or adenosine (P>0.05). Most importantly, CVT-3146 resulted in a markedly smaller decrease in TPR compared to that induced by adenosine, even though CVT-3146 and adenosine caused a similar peak increase in CBF and a comparable decrease in LDCR. Figure 3 shows the ratio between the decrease in LDCR and the decrease in TPR for CVT-3146 and adenosine (0.5 vs. 50µg/kg and 1.0 vs. 100µg/kg, respectively, both P<0.05). The ratio of LDCR:TPR for CVT-3146 was significantly greater than that for adenosine. adenosine. MBF increased by 18±4, 28±8, 48±8, 69±6, and 88±14% from 216±31mL/min (all P<0.05) following respective injections of CVT-3146 at doses of 0.1, 0.25, 0.5, 1.0, and 2.5µg/kg; MVR decreased by 15±3, 18±5, 32±4, 40±3, and 48±3%, respectively, from 0.58±0.10mmHg/mL/min (all P<0.05). Adenosine at doses of 10, 25, 50, 100, and 250µg/kg increased MBF by 36±8, 46±10, 66±9, 72±10, and 84±5%, respectively, from 211±26ml/min (all P<0.05); MVR decreased by 26±5, 29±5, 41±4, 43±5, and 49±2%, respectively, from 0.57±0.09mmHg/mL/min (all P<0.05) following injections of adenosine. There were no significant differences in the increase in MBF or the decrease in MVR in response to administration as compared to adenosine.
Effects of CVT-3146 or Adenosine on the Blood Flow in the Lower
As shown in Figure 6 , adenosine resulted in a dose-dependent decrease in RBF and a dose-dependent increase in RVR. Adenosine at doses of 10, 25, 50, 100, and 250µg/kg decreased RBF by 46±7, 54±5, 71±6, 80±5, and 85±4%, respectively, from 246±27ml/min (all P<0.05) and increased RVR by 109±30, 125±26, 309±80, 545±174, and 683±197%, respectively, from 0.49±0.09 mmHg/mL/min (all P<0.05). In contrast, CVT-3146 had no effect on RBF or RVR (Figure 6 ). At the highest dose of CVT-3146 (2.5µg/kg), a small but significant decrease in RBF (11±4%, P<0.05 compared to the baseline) was observed. 
Effects of CVT-3146 or Adenosine on Blood Pressure and Heart Rate

DISCUSSION
The coronary vasodilator effect of adenosine is the basis for its use in pharmacologic stress testing. Unfortunately, pharmacologic stress induced by adenosine is often associated with a high incidence of side effects including dyspnea, chest pain, and atrioventricular nodal block (Mahmarian and Verani, 1994; McGuinness and Talbert, 1994; Marwick 1997) . The atrioventricular nodal block is mediated by A 1 AdoR. Some evidence suggests that A 2B AdoR may play a role in increasing airway resistance (Fozard and Hannon, 1999) . This implies that the A 2B AdoR might be responsible for the dyspnea that occurs in pharmacologic stress testing.
Because a number of side effects induced by adenosine appear to be mediated by AdoR subtypes other than the A 2A receptor, it is presumed that selective agonists of A 2A receptors would cause fewer undesirable effects.
CVT-3146 is a novel A 2A AdoR agonist. Our previous results have indicated that, in conscious dogs, CVT-3146 is a more potent coronary vasodilator than adenosine (Trochu et al., 2003) . The present study demonstrates that the administration of CVT-3146 or adenosine results in a dose-dependent increase in CBF and a dose-dependent decrease in LDCR. Although the maximal increases in CBF were not significantly different, the ED 50 values of CVT-3146 and adenosine necessary to increase CBF were 0.45±0.07µg/kg and 47±7.77µg/kg, respectively (p<0.05), indicating that, as a coronary vasodilator, CVT-3146 is 100-fold more potent than adenosine.
CVT-3146 or adenosine also caused dose-dependent decreases in TPR, however, the decrease in TPR following the administration of CVT-3156 was significantly smaller than that induced by adenosine (Figure 1) . The smaller decrease in TPR by CVT-3146 may account for the smaller hypotension caused by CVT-3146 as compared to adenosine (Table 1) the ratios between decreases in LDCR and TPR observed with CVT-3146 were markedly greater than those for adenosine (Figure 3) , confirming that CVT-3146 is a more selective coronary vasodilator than adenosine.
The duration of the coronary vasodilation induced by pharmacologic stress testing agents is an important determinant of their usefulness. Because adenosine has an ultra-short duration of action, it is usually administered intravenously for 4-6 minutes to achieve the desired coronary vasodilation during stress testing (Mahmarian and Verani, 1994; McGuinness and Talbert, 1994; Allison et al., 1996; Leppo, 1996; Marwick, 1997; Cerqueira, 2000) . Several potent, highaffinitive, selective A 2A AdoR agonists, such as CGS-21680 and WRC-0470, have been developed (Glover et al., 1996; Alberti, 1997; Belardinelli et al., 1998; Shryock et al., 1998; Gao et al., 2001a) . Our previous results have shown that these two agents have excessively prolonged coronary vasodilator effects in the isolated rat heart (Gao et al., 2001a) , which may limit the clinical usefulness of these agents in pharmacologic stress testing because of their potential to cause significant hypotension. While the duration of coronary vasodilation caused by CVT-3146 is longer than that seen with adenosine (Figure 2) , there was no significant difference in the magnitude of the peak increase in CBF produced by the two agents. The duration of CBF 2-fold above the baseline was 130±19 sec. for CVT-3146 (2.5 µg/kg) and 16±3 sec. for adenosine (250 µg/kg) (P<0.05). These results clearly indicate that CVT-3146 yields a longer duration of coronary vasodilation than adenosine. Furthermore, CVT-3146 may be administered by a single injection during radionuclide myocardial perfusion imaging, thereby simplifying the procedure.
Our recent study in humans has revealed that CVT-3146 can cause a dose-dependent coronary vasodilation following a bolus intravenous injection. The profile of coronary vasodilation by CVT-3146 in humans is very similar to that found in conscious dogs in the present study (Kerensky et al., 2002) . This provides another piece of evidence to support that CVT-3146 could This is in keeping with previous studies (McCoy et al., 1993; Shryock and Belardinelli, 1997; Pelueger et al, 1999) , in which the administration of adenosine yielded afferent arteriolar constriction, an effect mediated by A 1 AdoR. Our findings are consistent with the idea that CVT-3146 does not activate A 1 AdoR (Gao et al., 2001a) , and the lack of renal vasoconstriction by CVT-3146 is yet another benefit of using this agent in pharmacologic stress testing. The which is a potentially undesirable effect. More importantly, renal vasoconstriction by adenosine is invisible and difficult to recognize, and may impair renal function. Elderly patients and those with coronary arterial disease whose renal function is already diminished may be at the greatest risk for adenosine-induced renal vasoconstriction. Because CVT-3146 has little or no effect on renal blood flow, it is unlikely to induce renal dysfunction when used in pharmacologic stress testing.
Some studies showed that adenosine could increase sympathetic nerve activity in humans, thereby causing direct tachycardia (Biaggioni et al, 1991; Lucarini et al, 1992; Engelstein et al, 1994) . The present results have also shown that there is a significant increase in heart rate or tachycardia following injections of CVT-3146 or adenosine. However, as shown in Figure 7 , the patterns of the tachycardia induced by CVT-3146 and adenosine were significantly different. This suggests that the mechanism(s) responsible for tachycardia caused by and adenosine may be different. Adenosine-induced tachycardia in conscious dogs was of short duration and mostly due to the baroreflex effect caused by hypotension. This reflex tachycardia overcomes bradycardia, which is the direct depressant effect of adenosine on HR and is mediated by A 1 AdoR (Gao et al., 2001b) . Our previous work showed that vagal tone might play an important role in adenosine-induced tachycardia in normal conscious dogs, because the blockade of muscarinic receptors or bilateral vagotomy could unmask adenosine-induced bradycardia in normal, conscious dogs (Belloni and Hintze, 1987; Belloni et al., 1989; Hintze et al., 1985) .
Moreover, adenosine resulted in bradycardia in conscious dogs after the development of pacinginduced heart failure, in which vagal tone is reduced (Belloni et al., 1992) . In contrast, our current results show that CVT-3146-induced tachycardia lasts much longer than that caused by adenosine, especially at higher doses (1.0 and 2.5µg/kg). The tachycardia lasted up to 4-5 min following the injection of a 2.5µg/kg dose of CVT-3146 (Figure 7) . Whether CVT-3146-This article has not been copyedited and formatted. The final version may differ from this version. induced tachycardia observed in the present studies is due to the increased sympathetic nerve activity remains to be determined.
It has been reported that the increased endogenous adenosine induced by dipyridamole could cause hyperventilation in conscious humans (Engelstein et al, 1994) , which is mediated by peripheral chmoreceptor activation since peripheral chemoreceptor suppression (with hyperoxia) abolished hyperventilation induced by dipyridamole. Adenosine-induced hyperventilation can result in changes in CBF and HR indirectly. We did not measure ventilation in our present studies quantitatively, although hyperventilation was observed in some dogs during the administration of CVT-3146 or adenosine. This is one of limitations of our studies.
In summary, our study indicates that CVT-3146 is a 100-fold more potent coronary vasodilator than adenosine, producing a longer duration of coronary vasodilation that may be useful in pharmacologic stress testing. CVT-3146 also causes a smaller decrease in total peripheral resistance and a smaller increase in LBF than that induced by adenosine, suggesting CVT-3146 is more selective for coronary than for peripheral vasodilation. This study also demonstrates that CVT-3146 causes no renal vasoconstriction. These features make CVT-3146 a promising candidate for pharmacologic stress testing with myocardial perfusion imaging using radionuclides for the diagnosis of coronary artery disease.
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